Scholars Central

Conference abstractPublished 26 Oct 2016

Pricing, public health, & politics: policy considerations for orphan products

Authors: Anne Marie Finley

Biotech Policy Group LLC, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Drug prices in the United States are higher than anywhere else in the world. Orphan products have long been perceived as pricier than many other drugs by payers, manufacturers and consumers. The Affordable Care Act’s expansion of insurance coverage and pharmaceutical benefits, along with a growing resistance to higher priced therapies, have added to the pharmaceutical pricing stress on the healthcare system and ultimately rare disease patients. Innovative responses to the current pharmaceutical pricing crisis have been developed by some drug companies, patient organizations, payers, regulators and legislators. The new Congress and new Administration have a number of options and opportunities by which to address pricing concerns in 2017.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectPublic Health & Epidemiology
  • SubjectSocial Sciences & Humanities
  • BylineArticles whose byline prints “Anne Marie Finley”